A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis Clinical Trial

— VISIONMS-LTE  

Official title:

VISIONARY-MS LTE: A Multi-Center, Open-Label Long-Term Extension Study Assessing the Safety, Efficacy, Tolerability, and Pharmacokinetics of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04626921
• Other study ID #: CNMAu8.201LTE
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: October 22, 2020
• Est. completion date: September 6, 2023

Study information

• Verified date: December 2023
• Source: Clene Nanomedicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Open-label, long-term extension study available to participants who have completed CNMAu8.201.

Description:

This open-label, long-term extension study is only available to participants who have completed CNMAu8.201 (VISIONARY-MS). The Week 48/End-of-Study Visit for study CNMAu8.201 (VISIONARY-MS) will serve to establish the Baseline for electrophysiological, functional, morphological vision testing, as well as the neurological and outcome assessments. Participants will receive open-label CNM-Au8 throughout the study. All participants will receive a daily dose of 30 mg CNM-Au8 for the entire open-label, long-term extension study. The dose for participants may be adjusted once efficacy and safety data from study CNMAu8.201 becomes available, which may occur after participants have already started this study. Based upon a review of data and Sponsor or PI recommendation, this open-label, long-term extension study may be discontinued once each participant reaches her/his 48-week visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: September 6, 2023
• Est. primary completion date: May 29, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Participants must have completed study CNMAu8.201.

• Able to understand and give written informed consent.

Exclusion Criteria:

• Lack of treatment compliance during participation in the CNMAu8.201 (VISIONARY-MS) study.

• Positive pregnancy test.

• Any history of previous malignancy, with the exception of basal cell carcinoma of the skin or in situ carcinoma of the cervix, post documented full resections, with clean margins.

• Based on the Investigator's judgment, any concurrent chronic or acute illness or unstable medical condition that could confound the results of safety assessments, increase risk to the participant, or lead to difficulty complying with the protocol; any untreated or unstable psychiatric disease including depression, bipolar and psychosis.

• Participant is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation.

Following clinical and serology sample analysis conducted at the end-of-study visit for CNMAu8.201 (VISIONARY-MS), participants may be removed from this long term extension study if any of the following criteria are met, at the discretion of the Medical Monitor and/or Sponsor's Medical Representative:

• Positive serology for viral hepatitis B and/or C and/or human immunodeficiency virus (HIV).

• Abnormal liver function tests (aspartate aminotransferase [ASAT] or alanine aminotransferase [ALAT] > 2x upper limit of normal range (ULN) or total bilirubin > 2x ULN or alkaline phosphatase (AP) > 3x ULN).

• Participants with clinically significant hepatic or renal dysfunction or clinical laboratory findings that would limit the interpretability of change in liver or kidney function (e.g., glomerular filtration rate < 40 mL/min [based on creatinine clearance according to Cockcroft-Gault equation]), or those with low platelet counts (<150 x 109 per liter) or eosinophilia (absolute eosinophil count of =500 eosinophils per microliter) at the EOS visit for CNMAu8.201 (Visionary-MS).

Related Conditions & MeSH terms

• Multiple Sclerosis
• Relapsing Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• CNM-Au8
30 mg of CNM-Au8

Locations

Country	Name	City	State
Australia	Sydney Brain Mind Centre	Camperdown	New South Wales
Australia	Menzies Institute for Medical Research	Hobart	TAZ
Australia	The Alfred Centre Department of Neuroscience	Melbourne	Victoria
Australia	John Hunter Hospital	New Lambton Heights	New South Wales
Australia	Princess Alexandra Hospital	Woolloongabba	Queensland

Sponsors (2)

Lead Sponsor	Collaborator
Clene Nanomedicine	George Clinical

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in best corrected Low-Contrast Letter Acuity score for total number of correct letter.	BC-LCLA score is the sum of all correctly identified letters up to the last line on the 2.5% Sloan Chart able in which three (3) or more letters are correctly read plus all correct letters on the following line. Scale is 70 - 0 with 70 being able to see all letters, 0 was unable to read any letters.	2 years
Other	Change in Best Corrected High Contrast Visual Acuity	Mean change from Baseline in best-corrected high contrast visual acuity (BCHCVA), as measured by EDTRS in the affected and fellow eye. Scale is 70 - 0 with 70 being able to see all letters, 0 was unable to read any letters.	2 years
Other	VEP latency for Multi-Focal visual evoked potential.	Mean change in average mf-VEP latency for the affected eye from the average Baseline mf-VEP latency of the affected eye.	2 years
Other	VEP latency for Full Field Visual Evoked Potential	Mean change in average ff-VEP latency for the affected eye from the average Baseline ff-VEP latency of the affected eye.	2 years
Other	VEP Amplitude for Multi-Focal Visual Evoked Potential	Mean change in average amplitude for the affected eye from the average Baseline of the affected eye (for all measurable segments).	2 years
Other	VEP Amplitude for Full Field Visual Evoked Potential	Mean change in average amplitude for the affected eye from the average Baseline of the affected eye (for all measurable segments).	2 years
Other	OCT of the Retinal Nerve Fiber Layer (RNFL) by Peripapillary Scan	Percentage change in average thicknesses of the RNFL for the affected eye and the fellow eye from their respective Baselines.	2 years
Other	OCT of the Retinal Layers by Macular Scan evaluating Ganglion cell and inner plexiform.	Percentage change in mean thicknesses of the GCIP for the affected eye and the fellow eye from their respective Baselines as determined by segmentation of SD-OCT.	2 years
Other	OCT of the Retinal Layers by Macular Scan evaluating Ganglion cell layer.	Percentage change in mean thicknesses of the GCL for the affected eye and the fellow eye from their respective Baselines as determined by segmentation of SD-OCT.	2 years
Other	OCT of the Retinal Layers by Macular Scan evaluating Inner nuclear layer.	Percentage change in mean thicknesses of the inner nuclear layer for the affected eye and the fellow eye from their respective Baselines as determined by segmentation of SD-OCT.	2 years
Other	OCT of the Retinal Layers by Macular Scan evaluating outer nuclear layer.	Percentage change in mean thicknesses of the outer nuclear layer for the affected eye and the fellow eye from their respective Baselines as determined by segmentation of SD-OCT.	2 years
Other	MRI Evaluation of the Mean change in whole brain and OR T2 lesion volume.	Mean change in whole brain and OR T2 lesion volume from Baseline	2 years
Other	MRI Evaluation of the Mean change in whole brain and optic radiation T1 hypo-intense lesion volume.	Mean change in whole brain and optic radiation T1 hypointense lesion volume from Baseline.	2 years
Other	MRI Evaluation of the Proportion of Baseline Gd+ lesions converting to black holes.	Proportion of Baseline Gd+ lesions converting to black holes.	2 years
Other	MRI Evaluation of the Volume of Baseline Gd+ lesions converting to T1 hypointense lesions.	Volume of Baseline Gd+ lesions converting to T1 hypointense lesions.	2 years
Other	MRI Evaluation of the Mean percent whole brain volume change (PBVC) from baseline.	Mean percent whole brain volume change (PBVC) from baseline.	2 years
Other	MRI Evaluation of the Mean Percent Cerebral Cortical Change from Baseline	Mean Percent Cerebral Cortical Change from Baseline	2 years
Other	MRI Evaluation of the Mean Percent Thalamic Volume Change from Baseline.	Mean Percent Thalamic Volume Change from Baseline.	2 years
Other	MRI Evaluation of the Mean Percent Deep Grey Nuclei Volume Change from Baseline.	Mean Percent Deep Grey Nuclei Volume Change from Baseline	2 years
Other	MRI Evaluation of the Mean change in number of whole brain new/enlarging T2 lesion(s) from baseline.	Mean change in number of whole brain new/enlarging T2 lesion(s) from baseline.	2 years
Other	Mean change in whole brain DTI/MTR from baseline.	DTI- Diffusion Tensor Imaging, MTR- Magnetization Transfer Ratio.	2 years
Other	Mean change in optic radiation lesional/non-lesional fibre DTI / MTR difference from Baseline (fiber based, individually reported for each baseline OR lesion).	Individual OR lesion MRI analysis	2 years
Other	Mean change in MWF from Baseline in the whole brain.	Myelin Water Fraction MRI Analysis	2 years
Primary	Change in Best-Corrected Low-Contrast Letter Acuity score.	Mean change in BC-LCLA from baseline to end of study across all eyes as measured by 2.5% low contrast Sloan Letter Chart.	2 years
Primary	Incidence of treatment-emergent AEs throughout the study.	Safety endpoint include incidence of treatment-emergent AEs.	2 years
Secondary	Measure of neurological function assessed by a functional composite responder analysis.	Mean change in Functional Composite Responder Analysis Score from Baseline to End of Study.	2 years